CD274 and neoplasm: Likewise, in a post-hoc, exploratory analysis in the combined discovery and validation cohorts, we identified an ultra-low subset of the IRS-L population that shows particularly poor PD-(L)1 rwPFS and OS (Figure S18 & S19), suggesting that it may be possible to identify patients more likely to benefit from other therapies in PD-(L)1 approved tumor types when therapeutic choice is present.